Core Insights - DaVita Inc. is a kidney dialysis service provider valued at $9 billion, with earnings announcement for Q3 2025 expected on October 29 [1] - Analysts project a profit of $3.29 per share for Q3 2025, reflecting a 27% increase from $2.59 per share in the same quarter last year [2] - For the full fiscal year 2025, EPS is anticipated to be $10.93, a 12.9% rise from $9.68 in fiscal 2024, with further growth expected to $12.73 in fiscal 2026 [3] Performance Analysis - DaVita's stock has underperformed, declining 24% over the past 52 weeks, compared to a 13.5% gain in the S&P 500 Index and a 7.2% loss in the Health Care Select Sector SPDR Fund [4] - The company's disappointing performance is attributed to a year-over-year decline in normalized non-acquired treatment and pressure on adjusted operating margins [5] Recent Financial Results - In Q2, DaVita reported revenue of $3.4 billion, a 6.1% increase year-over-year, with adjusted EPS of $2.95, up 47.5% from the previous quarter [6] Analyst Ratings - The consensus rating for DaVita stock is "Hold," with one "Strong Buy," seven "Hold," and one "Moderate Sell" among nine analysts [7] - The average analyst price target for DaVita is $150.86, suggesting a potential upside of 20.4% from current levels [7]